Biosig Technologies (BSGM)
(Delayed Data from NSDQ)
$1.37 USD
+0.07 (5.38%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.37 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.37 USD
+0.07 (5.38%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.37 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Cooper Companies (COO) Q3 Earnings Match Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
by Zacks Equity Research
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sientra (SIEN) delivered earnings and revenue surprises of 3.41% and 7.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 25% and 7.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 5.68% and 2.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
by Zacks Equity Research
The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies
by Zacks Equity Research
ShockWave Medical, CheckCap and Biosig Technologies are part of The Zacks top Analyst Blog.
3 Medical Instruments Stocks With Potential to Outperform
by Zacks Equity Research
Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.
Mesa Labs (MLAB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 18.09% and 6.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -140.80% and 23.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 233.33% and 65.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sorrento & ViralClear Explore Combination Coronavirus Treatments
by Zacks Equity Research
Sorrento (SRNE) collaborates with ViralClear Pharmaceuticals to evaluate the combination of antibody and antiviral assets against COVID-19.
BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia
by Zacks Equity Research
BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.
BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
by Zacks Equity Research
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
Moving Average Crossover Alert: Biosig Technologies, Inc.
by Zacks Equity Research
Biosig Technologies could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.